Efficacy, long‐term safety, and impact on quality of life of elobixibat in more severe constipation: Post hoc analyses of two phase 3 trials in Japan

por Nakajima, Atsushi, Taniguchi, Shinya, Kurosu, Shinsuke, Gillberg, Per‐Göran, Mattsson, Jan P., Camilleri, Michael
Publicado 2019

Impact of elobixibat on serum and fecal bile acid levels and constipation symptoms in patients with chronic constipation

por Nakajima, Atsushi, Ishizaki, Sonoko, Matsuda, Kazuki, Kurosu, Shinsuke, Taniguchi, Shinya, Gillberg, Per‐Göran, Mattsson, Jan P, Hasunuma, Tomoko, Camilleri, Michael
Publicado 2022

A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multiorgan activity and shows translational relevance to humans

por Caballero-Camino, Francisco J., Rodrigues, Pedro M., Wångsell, Fredrik, Agirre-Lizaso, Aloña, Olaizola, Paula, Izquierdo-Sanchez, Laura, Perugorria, Maria J., Bujanda, Luis, Angelin, Bo, Straniero, Sara, Wallebäck, Anna, Starke, Ingemar, Gillberg, Per-Göran, Strängberg, Ellen, Bonn, Britta, Mattsson, Jan P., Madsen, Martin R., Hansen, Henrik H., Lindström, Erik, Åkerblad, Peter, Banales, Jesus M.
Publicado 2023

Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis

por Thompson, Richard J., Artan, Reha, Baumann, Ulrich, Calvo, Pier Luigi, Czubkowski, Piotr, Dalgic, Buket, D’Antiga, Lorenzo, Di Giorgio, Angelo, Durmaz, Özlem, Gonzalès, Emmanuel, Grammatikopoulos, Tassos, Gupte, Girish, Hardikar, Winita, Houwen, Roderick H.J., Kamath, Binita M., Karpen, Saul J., Lacaille, Florence, Lachaux, Alain, Lainka, Elke, Loomes, Kathleen M., Mack, Cara L., Mattsson, Jan P., McKiernan, Patrick, Ni, Quanhong, Özen, Hasan, Rajwal, Sanjay R., Roquelaure, Bertrand, Shteyer, Eyal, Sokal, Etienne, Sokol, Ronald J., Soufi, Nisreen, Sturm, Ekkehard, Tessier, Mary Elizabeth, van der Woerd, Wendy L., Verkade, Henkjan J., Vittorio, Jennifer M., Wallefors, Terese, Warholic, Natalie, Yu, Qifeng, Horn, Patrick, Kjems, Lise
Publicado 2023